As statins may contribute to plaque stabilisation, it is important to evaluate whether these drugs may modify arterial stiffness. In 23 patients, aged 32-70 years, with hypertension and hypercholesterolaemia, a doubleblind randomised study vs placebo was performed to evaluate whether atorvastatin was able to modify aortic stiffness, measured from aortic pulse wave velocity (PWV), after a 12-week treatment. The results revealed that atorvastatin did not change blood pressure, significantly lowered (Po0.003; o0.002) plasma total and LDL cholesterol, and increased aortic PWV by +8% (vs À2% under placebo) (P40.05). The percentage changes in plasma total and LDL cholesterol and in PWV were significantly and negatively correlated, independent of blood pressure level. The finding of increased aortic PWV after 12-week statin treatment agrees with studies in monkeys, indicating that, at the early phase of hypolipidaemic diet but not later, aortic PWV increases transiently as a consequence of the significant reduction of lipid vascular content. In conclusion, the present results support the possibility that statins might contribute to a change in arterial stiffness independent of blood pressure level, and suggest that long-term studies in humans are needed to evaluate the contribution of arterial elasticity to statin-induced vascular remodelling.
Introduction
Increased arterial stiffness is an independent predictor of cardiovascular (CV) risk in normotensive and hypertensive populations. 1 Studies in subjects with high CV risk have shown that the reduction of CV morbidity and mortality is significantly improved when the blood pressure reduction is associated with arterial stiffness attenuation. 2 Deceased subjects have the same blood pressure reduction as survivors but no reduction of arterial stiffness. From these results, it seems likely that drugs reducing arterial stiffness are important to consider in CV prevention. The drug effects on arterial elasticity are well established for antihypertensive agents 3 but remain to be documented for lipid-lowering medications.
In subjects with hypercholesterolaemia and/or atherosclerosis, wide variations in arterial stiffness are expected to occur since the vessels are composed of both soft (lipids) and rigid (sclerosis) tissue. [4] [5] [6] [7] Subsequently, lipid-lowering agents may have various consequences on arterial stiffness. First, statins are known to have a beneficial effect on endothelial function, thereby restoring nitric oxide (NO) bio-activity in atherosclerotic populations 8, 9 and thus producing an NO-induced large artery dilatation and reduction of stiffness. 3 Secondly, statins cause, at an early phase, a rapid reduction of lipid vascular content, and thereby may be responsible for an absolute or relative increase in collagen, a process causing an increase of arterial stiffness. [10] [11] [12] Finally, in subjects with hypercholesterolaemia, statin treatments are associated with either decreased or unchanged alterations of arterial stiffness. 13, 14 In subjects with hypertension, the situation may be even more complex to evaluate since increased stiffness may be the consequence of both high blood pressure and intrinsic modifications of the arterial wall. 3 Combined effects of hypertension and hypercholesterolaemia are known to result in a further increase of arterial stiffness, at least at the site of the radial artery. 15 Whether statin treatment may reduce, increase, or not modify arterial stiffness has been poorly investigated in hypercholesterolaemic hypertensive subjects pharmacologically treated for both CV risk factors.
The purpose of the present study was, in patients treated for hypertension and hypercholesterolaemia, to evaluate whether aortic stiffness, measured from aortic pulse wave velocity (PWV), was modified following a 12-week treatment by the hypolipidaemic agent atorvastatin.
Materials and methods
The present controlled, randomised, double-blind, two-parallel-group study was conducted in the Department of Internal Medicine of Broussais Hospital (Paris). In total, 29 patients, aged 32-70 years, were preincluded for hypertension and hypercholesterolaemia by general practitioners. The inclusion criterion for high blood pressure was a mild-to-moderate essential hypertension defined as a supine systolic blood pressure (SBP) X160 and o210 mmHg, and/or a supine diastolic blood pressure (DBP) X95 and o110 mmHg, or the presence of sustained antihypertensive drug therapy (see below). For hypercholesterolaemia, the criterion of inclusion was the elevated plasma LDL cholesterol after a one-month hypolipidaemic regimen. The LDL plasma levels were chosen to be either 4.9 or 3.4 mmol/l, depending in each individual on the number of associated CV risk factors or the presence of personal history of coronary heart disease. 16, 17 After a one-month washout placebo period with hypolipidaemic regimen, 28 of the 29 patients (16 men; 12 women) fulfilled these criteria and were included in the study. The mean age was 56.9 years (range: 32-70 years). Body weight and height were 78710 kg and 16479 cm (71 s.d.), respectively. Signs, symptoms or history of secondary or malignant hypertension, strokes, major cardiac or renal diseases, lower limb arteritis, stage IV retinopathy, familial hypercholesterolaemia, known hepatic disease, treated diabetes, severe obesity, EKG abnormalities, or therapeutic contra-indications (to statins) were the main exclusion criteria. For the overall population, the mean values of plasma potassium, creatinine, uric acid, glucose, and hepatic enzymes were within the normal range and remained unmodified along the study. Written informed consent was obtained from each subject and the protocol was approved by our institutional Ethics Committee.
Following the washout placebo period, 23 patients entered a 12-week double-blind active treatment period, and were randomly allocated to either atorvastatin (n ¼ 12) or placebo (n ¼ 11). Atorvastatin was given at a classic dosage of 10 mg/day, based on therapeutic trials using long-term double-blind titration, 16, 17 thus establishing the drug effectiveness on plasma lipids as the primary goal of the investigation. In both groups, the medication was taken orally as a single dose at 20h00. No withdrawal from the protocol was observed during the study.
Haemodynamic investigations were performed at the end of the preinclusion placebo period and at the end of the follow-up. Each subject was investigated at 10h 00 in a controlled environment of 22721C. After a 20-min rest in the supine position, brachial SBP and DBP and heart rate were determined using a mercury sphygmomanometer fitted on the left arm. Then, arterial measurements were performed, involving both carotid pulse wave analysis and carotid-femoral PWV determinations. The latter were analysed by two physicians blinded to treatment, clinical data, and physical examination.
Carotid-femoral (aortic) PWV was determined using an automatic device, the Complior (Colson, Paris), which allows on-line pulse wave recording and automatic calculation of PWV. 18 Briefly, common carotid artery and femoral artery pressure waveforms were recorded noninvasively with a pressure-sensitive transducer. The pressure waveforms were digitised at a sample acquisition frequency of 800 Hz. The two pressure waveforms were then stored in a memory bank. A preprocessing system automatically analysed the gain in each waveform and adjusted it to equalise the two signals. Details of this procedure have been published previously. 18 When the operator observed a pulse waveform of sufficient quality on the computer screen, digitisation was suspended and calculation of the time delay between the two pressure upstrokes was initiated. Measurement was repeated over 10 different cardiac cycles, and the mean was used for the final analysis. The distance travelled by the pulse wave was measured over the body surface as the distance between the two recording sites (D), whereas pulse transit time (t) was automatically determined by the Complior. PWV was automatically calculated as PWV ¼ D/t. Validation and reproducibility of this automatic method have been reported previously. 18 For carotid pulse pressure (PP) determinations, brachial and radial artery SBP, DBP, and mean blood pressures (MBP) were considered equivalent, taking into account the small degree of pressure wave amplification between these two sites. 18, 19 The carotid pressure wave was measured by applanation tonometry and calibrated from the brachial pressure wave, assuming that the MBP (determined from integration of the digitized radial pressure wave) was the same at both sites and that brachial and carotid DBP were nearly equal. [18] [19] [20] The carotid MBP was computed from the area of the carotid pressure wave in the corresponding heart period and set equal to brachial MBP. Carotid pressure amplitude was then computed from the DBP and the position of MBP on the carotid pressure wave. [18] [19] [20] Carotid PP was averaged for a series of waves over a 10-s period. The repeatability coefficients after one-and three-month intervals were 6.8 and 7.2 mmHg, respectively. On the carotid blood pressure curve, the carotid augmentation index, a classic marker evaluating the delay of wave reflections and its role in the height of carotid SBP, was determined according to previously validated methods. 19, 20 Statistical analysis Data are expressed as mean value 7s.d. or as adjusted means 7s.e. Because of the sample size of treatment groups, we took residual values of parameter regression on age, gender, and MBP at baseline as variables analysed by the Kruskal-Wallis test according to the treatment factor. The relationships between changes in PWV and changes in lipid parameters were studied using the Spearman correlation coefficients after adjustment on age, gender, and baseline MBP. A P-value below or equal to 0.05 was considered to be significant. Table 1 indicates the baseline characteristics of the hypertensive population. Brachial blood pressures were somewhat lower in the placebo than in the statin group, but the difference was not significant. Antihypertensive drug treatment did not differ between the two groups, including in each group respectively: diuretics (n ¼ 6 and 7); converting enzyme inhibitors (n ¼ 5 and 4); calcium entry blockers (n ¼ 4 and 5); beta blocking agent (n ¼ 5 and 5); miscellaneous (n ¼ 2 and 3). Table 2 compares the observed changes (%) in plasma lipids and in PWV in the statin and in the placebo group. With statin, there was a significantly lower plasma total and LDL cholesterol than with placebo: the differences were highly significant (Po0.003; Po0.002). Aortic PWV was significantly higher (Po0.05) under statin than under placebo. PWV increased by 7.7373.99% under statin (P ¼ 0.07) and slightly decreased under placebo (À2.2874.69; NS). Brachial and carotid blood pressure did not differ significantly between statin and placebo groups.
Results
In the totality of the population, the percentage change in PWV was negatively correlated to baseline MBP (r ¼ À0.39; Po0.08) and mostly to the changes in plasma total cholesterol (r ¼ À0.42; Po0.08) and LDL cholesterol (r ¼ À0.48; Po0.04). The latter findings were observed even after adjustment for age, gender, and baseline MBP.
Comments
In this report, statin treatment was associated with a significantly lower value of decrease in plasma total and LDL cholesterol than placebo. The finding was associated with a slight increase of aortic PWV, together with a significant negative correlation between the change in PWV and the change in plasma lipid parameters. No significant change in blood pressure was observed.
In the present study, we used PWV as a marker of aortic stiffness, since this parameter is related to the square root of the elasticity modulus and to the thickness/radius ratio. The PWV, determined from foot-to-foot transit time in the aorta, offers a simple, reproducible and noninvasive evaluation of regional aortic stiffness. This noninvasive superficial measurement allows only an estimate of the distance travelled by the pulse, and accurate measurements of this distance are obtained only with invasive procedures. In this regard, some authors suggested a possible correction based on anatomic dimensions 71 s.d. n: number of subjects; BMI: body mass index; DBP: diastolic blood pressure; LDL/HDL: low-density/high-density lipoprotein; MBP: Mean blood pressure; PP: pulse pressure; PWV: pulse wave velocity; SBP: systolic blood pressure.
Effects of atorvastatin on aortic PWV J Raison et al of the body, 21 whereas others recommended subtracting the distance between the suprasternal notch and the carotid location from the total distance when the carotid pulse is recorded instead of the aortic arch pulse, because the pulse wave travels in the opposite direction at that level. 18, 19 In fact, this correction is not useful for clinical pharmacology procedures since only the changes and not the absolute values of PWV are considered. Repeatability studies, checks made with BlandAltman diagrams, and modern computer technology made it quite feasible simply to investigate aortic stiffness in CV drug studies. Since the principal factors modulating the level of PWV are age and blood level, [18] [19] [20] studies using PWV should adjust the values obtained to these two dominant parameters, as carried out in this report.
The findings of this investigation should be interpreted very cautiously. The primary goal of the study was to reduce plasma total and LDL cholesterol, a result that was easily achieved with a small number of subjects. However, published data in the literature suggest that about 40 patients would be needed to detect a 10% change in PWV using a parallel group design. 22 Therefore, regarding PWV changes, the present results should be considered only as preliminary. Nevertheless, the design, which included the presence of antihypertensive agents in the population, was particularly adapted for the evaluation of stiffness changes as a function of their therapeutic implications. Because of the chronic use of antihypertensive agents, blood pressure was stable along the totality of the investigation and remained very close to normotensive values. Indeed, this situation did not allow the evaluation of whether statins might significantly reduce blood pressure, 23 but clearly showed that the PWV changes were roughly independent of blood pressure level, whether blood pressure was measured in the brachial or in the carotid arteries.
The major finding of this study was that after 12-week treatment by statin, aortic PWV slightly increased whereas blood pressure remained unmodified. In addition, no further decrease in DBP or increase in SBP was observed during the follow-up, as an expected response to the development of arterial stiffening. Finally, all these results taken together suggest a cause to affect the relationship between statin treatment and change in stiffness.
Studies in monkeys [24] [25] [26] [27] have previously shown that a diet regimen rich in cholesterol is associated in the long term with a significant pressureindependent increase of aortic PWV, and that following a chronic hypolipidaemic diet, the regimen is associated with a further transient increase of PWV, in relation with the reduction of the lipid vascular content, a biomaterial usually considered as soft. After this early phase, the increase in PWV tends to disappear and is even reversed as a consequence of the remodelling of the vascular wall. [10] [11] [12] 28 Such experimental findings agree with the slight increase in PWV that we observed in the present study after the 12-week treatment.
Such biphasic alterations agree with several recent findings on statins, indicating that these drugs are able, at the beginning of treatment, not only to reduce the lipid vascular content but also to increase the absolute or relative collagen content within atherosclerotic plaques and that vascular remodeling in humans is not observed after sixmonth treatment but only after 12 months. [8] [9] [10] [11] [12] 28 Furthermore, in patients with hypercholesterolaemia, radial artery compliance was found to increase to a larger extent after a two-year treatment than after a six-month treatment of simvastatin. 15, 29 Finally, all these findings taken together agree with the clinical observations that, although favourable changes in lesion composition were observed within three months of statin treatment, clinical trials suggest that event reduction takes six-twelve months after initiation of treatment. 30, 31 In conclusion, the present results suggest that during drug treatments involving CV prevention, statins might contribute to a change in arterial stiffness independent of blood pressure. Because in this study the number of patients was relatively small and because treatment was of short duration, further studies are needed to confirm these changes and their evolution following long-term hypolipidaemic drug treatment in hypertensive subjects.
